Suzhou HIGEN Pharmaceutical Technology Co., Ltd

Main objective: To study the pharmacokinetic characteristics of dapoxetine hydrochloride tablets (60 mg) developed by Suzhou Seaview Pharmaceutical Technology Co., Ltd. and produced by Shandong Weizhi Baike Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration; using dapoxetine hydrochloride tablets (Priligy ®, 60 mg) certified by Berlin-Chemie AG and produced by Menarini-Von Heyden GmbH as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.